EFFECT OF ZUOXINGDAN INJECTION ON PATIENTS WITH HEART FAILURE AFTER MYOCARDIAL INFARCTION AND ITS EFFECTS ON NT-PRO BNP, LVEDD, AND LVEF

Objective: To investigate the efficacy of Levosimendan on the treatment of heart failure after myocardial infarction and the serum N-terminal pro-brain natriuretic peptide (NT-pro BNP), left ventricular end-diastolic diameter (LVEDD), and the impact of the left ventricle ejection fraction (LVEF). Methods: Eighty-six patients with heart failure after myocardial infarction in our hospital from December 2014 to December 2016 were randomly divided into treatment group and control group with 43 cases in each group. On the basis of conventional treatment, the control group was given milrinone injection, and the treatment group was treated with levosimendan injection for one week. The clinical effects of the two groups after treatment, the changes in the serum NT-pro BNP, LVEDD, LVEF levels, and the occurrence of adverse reactions were compared. Results: The total effective rate of the treatment group after treatment was higher than that of the control group (90.70% vs. 67.44%) and the difference between the two groups was statistically significant (P<0.05). After treatment, serum NT-pro BNP, LVEDD, and LVEF were improved compared with those before treatment, but the treatment group was more obvious (P<0.05). The levels of serum IL-6, Hs-CRP, and TNF-alpha in the two groups were significantly lower than those before treatment (P<0.05). The levels of serum IL-6, Hs-CRP, and TNF-alpha in the treatment group were significantly lower than those in the control group, and the difference was statistically significant (P<0.05). The incidence of adverse reactions in the treatment group was lower than that in the control group, but the difference was not statistically significant (P>0.05). Conclusion: Levosimendan injection has obvious curative effects on heart failure after myocardial infarction, and effectively regulates the changes in the serum NT-pro BNP, LVEDD, and LVEF levels, enhancing myocardial contractility and reducing the incidence of adverse reactions, which is safe and reliable.